Acute Myeloid Leukemia (AML), an aggressive form of blood cancer, has long been a significant challenge for patients and doctors in India. But recent medical breakthroughs—including the recent approva ...

"Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri.

Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy approved in the management of cancer ...

Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea.

Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy ...

Servier today announced updates to two of its Phase 3 programs evaluating TIBSOVO (ivosidenib tablets) in isocitrate dehydrogenase 1 (IDH1)-mutated cancers. The first patient has been enrolled in ...

Two-fold increase in PFS with postoperative ivosidenib holds up in placebo-controlled trial ...

Ivosidenib and azacitidine Ivosidenib is a targeted cancer drug. It is also known as Tibsovo. Azacitidine is a chemotherapy drug. It is also called Vidaza. You pronounce ivosidenib as ...

Ivosidenib tablets are used to treat acute myeloid leukemia, a blood and bone marrow cancer in adults with a specific mutation whose condition has worsened or shown resistance with other medicines.